| Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer | 09/10 08:30 | globenewswire.com |
| Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? | 09/03 10:40 | zacks.com |
| Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference | 09/03 08:30 | globenewswire.com |
| Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice | 08/30 13:01 | zacks.com |
| Atossa Therapeutics Granted Additional Patent Protection for Endoxifen | 08/28 08:30 | globenewswire.com |
| Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer | 08/21 11:30 | globenewswire.com |
| Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations | 08/20 08:30 | globenewswire.com |
| Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update | 08/12 08:30 | globenewswire.com |
| Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer | 07/22 08:30 | globenewswire.com |